Form 4: Adaptive Biotechnologies COO Sells Shares
Insider Transaction (Form 4)
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, sold 35,643 shares of common stock on October 14, 2026.
Summary
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on October 14, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 6,781 Common Stock at $25.57 ($173,390) on October 14, 2026; holds 382,902 after (Direct).
- Open-market sale: disposed of 5,100 Common Stock at $25.82 ($131,682) on October 14, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on October 15, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 11,881 Common Stock at $25.61 ($304,272) on October 15, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on October 16, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 11,581 Common Stock at $24.21 ($280,376) on October 16, 2026; holds 378,102 after (Direct).
- Open-market sale: disposed of 300 Common Stock at $25.45 ($7,635) on October 16, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on October 14, 2026; holds 260,967 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on October 15, 2026; holds 249,086 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on October 16, 2026; holds 237,205 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $897,356 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Julie Rubinstein — Officer (President and COO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-14 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-10-14 | Open-market sale | Common Stock | 6,781 | $26 | $173.4K | 382,902 |
| 2026-10-14 | Open-market sale | Common Stock | 5,100 | $26 | $131.7K | 377,802 |
| 2026-10-15 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-10-15 | Open-market sale | Common Stock | 11,881 | $26 | $304.3K | 377,802 |
| 2026-10-16 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-10-16 | Open-market sale | Common Stock | 11,581 | $24 | $280.4K | 378,102 |
| 2026-10-16 | Open-market sale | Common Stock | 300 | $25 | $7.6K | 377,802 |
| 2026-10-14 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 260,967 |
| 2026-10-15 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 249,086 |
| 2026-10-16 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 237,205 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-14 | Option exercise/conversion (11,881 shares) |
| 2026-10-14 | Open-market sale (6,781 shares) |
| 2026-10-14 | Open-market sale (5,100 shares) |
| 2026-10-15 | Option exercise/conversion (11,881 shares) |
| 2026-10-15 | Open-market sale (11,881 shares) |
| 2026-10-16 | Option exercise/conversion (11,881 shares) |
| 2026-10-16 | Open-market sale (11,581 shares) |
| 2026-10-16 | Open-market sale (300 shares) |
| 2026-10-14 | Option exercise/conversion (11,881 shares) |
| 2026-10-15 | Option exercise/conversion (11,881 shares) |
| 2026-10-16 | Option exercise/conversion (11,881 shares) |
Keywords
insider transaction, Form 4, ADPT, Adaptive Biotechnologies Corp, bearish, Julie Rubinstein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.